BioSpace News Archive

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will participate in the 2022 BIO International Convention in San Diego from June 13-16, 2022.

Senti Biosciences, Inc. today announced the completion of its business combination with Dynamics Special Purpose Corp.

Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protection BARHEMSYS ® (amisulpride for injection) and BYFAVO ® (remimazolam for injection) join Eagle portfolio, with an estimated combined $3.1 billion per year 1 addressable market and projected annual peak sales of $275 2 million in the U.S.

GNS today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined GNS as a strategic advisor.

Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational drug, in patients with first-line metastatic pancreatic ductal adenocarcinoma.

Seelos Therapeutics, Inc. today announced data demonstrating a statistically significant (p<0.01) 19% downregulation of mRNA and a ~40% reduction of alpha synuclein (α-synuclein) in an in vitro study of SLS-004, its gene therapy program utilizing CRISPR-dCas9, in dementia with Lewy bodies (DLB).

Karius®, the world leader in liquid biopsy for infectious diseases, today announced a partnership with Capstone Health Alliance, a group purchasing organization focused on supply chain savings in hospitals and other organizations, to streamline patient access to the Karius Test®.

Ambys Medicines , a company pioneering cell-replacement therapies for patients with liver disease, today announced that data from its universal hepatocyte program will be presented at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, which will be held June 15-18, 2022, in San Francisco and virtually.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the Jefferies Global Healthcare Conference.

Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will participate in a webinar on Unlocking the Value of Digital Prescription Therapeutics hosted by Cowen to discuss the recently released promising pivotal clinical trial data for BT-001.